anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The incidence of coronavirus disease 2019 (COVID-19) in children has been increasing worldwide since the onset of the pandemic. This study examined the risk factors and characteristics of COVID-19 among pediatric patients compared to other respiratory viral infections.
METHODS: This was a prospective cross-sectional study. Patients aged 0-18 years presenting with respiratory symptoms from October 2020 to December 2021 were included. Demographic and clinical data were reviewed.
RESULTS: In total, 738 pediatric patients were enrolled. Of these, 48.5% had COVID-19, and 41.3% were infected with another respiratory virus. The COVID-19 incidence increased from 0.5% during the original strain outbreak (October 2020 to March 2021) to 56.5% and 73.4% during the alpha (April to June 2021) and delta (July to December 2021) periods, respectively. Children aged 6-18 years, being female, obesity, exposure to household members with COVID-19, and the delta period were risk factors for COVID-19. Being aged 1-5 years, obesity, shortness of breath, productive cough, and chest pain were associated with COVID-19 pneumonia. Children aged 5-18 years, underlying neurological disease, a history of COVID-19 pneumonia, and the delta period were associated with long COVID.
CONCLUSIONS: Pediatric COVID-19 patients presenting with respiratory symptoms who are obese or have been exposed to household members with COVID-19 should be tested for COVID-19. COVID-19 patients who are obese, younger than five years old, or who present with shortness of breath, productive cough, or chest pain should be evaluated for pneumonia. COVID-19 patients with a history of COVID-19 pneumonia or underlying neurological disease should receive follow-up for long COVID.
PURPOSE:To obtain a beatifying and whitening agent having excellent melanization inhibitory, beautifying and whitening effects without any side effects by blending S-lactoylglutathiones as an active ingredient with other ingredients. CONSTITUTION:A beautifying and whitening agent containing S- lactoylglutathione expressed by the formula and/or a salt thereof as an active ingredient. Commercially available products may be used as the compound expressed by the formula; however, the compound can also enzymically be produced from methylglyoxal and glutathione with glyoxalase I. The salt thereof can be produced from the compound expressed by the formula according to a conventional method. The aforementioned beautifying and whitening agent can be used by oral administration, parenteral administration (intramuscular, intracutaneous, subcutaneous or intravenous agent, suppository, ointment, etc.) or bathing. The dose for an adult is normally about 0.3 to 3000mg, preferably about 300mg at a time.
OBJECTIVES: To observe the effect of mind-regulating acupuncture on pain intensity, sleep quality, negative emotion in patients with postherpetic neuralgia (PHN), and evaluate the clinical effect of mind-regulating acupuncture combined with surrounding needling and heavy moxibustion at Ashi points (Extra) in treatment of PHN.
METHODS: The patients with PHN were randomly divided into a control group (35 cases, 2 cases dropped out) and a comprehensive therapy group (35 cases). The patients in the control group were treated with surrounding needling and heavy moxibustion at Ashi points. In the comprehensive therapy group, the mind-regulating acupuncture therapy was delivered besides the treatment as the control group. The treatment was given once daily, one course of treatment was composed of 6 days and 2 courses were required in the 2 groups. Before and after treatment, the pain conditions were assessed using pain rating index (PRI), visual analogue scale (VAS) and present pain intensity (PPI), the negative emotions were assessed using Hamilton anxiety scale (HAMA) and Hamilton depression scale (HAMD), and the sleep quality with Pittsburgh sleep quality index (PSQI). One week before and one week after treatment, the average sleep time was recorded. The therapeutic effect of 2 groups was evaluated. The effective cases of 2 groups were followed up in 2 months after treatment completion and the recurrence of neuralgia was recorded.
RESULTS: There were no statistical differences in the above indicators between the 2 groups before treatment. After 2 courses of treatment, the scores of PRI, VAS, PPI, HAMA, HAMD and PSQI were reduced when compared with those before treatment in the patients of the 2 groups (P<0.05), and the average sleep time was increased (P<0.05). The scores of PRI, VAS, PPI, HAMA, HAMD and PSQI in the comprehensive therapy group, as well as the average sleep time were all improved when compared with those of the control group (P<0.05). The total effective rate in the comprehensive therapy group (34/35, 97.14%) was higher than that of the control group (27/33, 81.82%, P<0.05) and the recurrence rate was lower ([2/34, 5.88%]vs[8/27, 29.63%], P<0.05).
CONCLUSIONS: The combination of mind-regulating acupuncture with surrounding needling and heavy moxibustion at Ashi acupoint can effectively relieve PHN. Compared with the traditional surrounding acupuncture in pain area combined with moxibustion at Ashi points, this comprehensive therapy is more effective for ameliorating pain intensity, improving sleep quality and reducing negative emotions. It is also effective for declining the recurrence.
The invention relates to a CdTe quantum dot-containing nano-artesunate capsule and its preparation method. The capsule is a nano-capsule taking the quantum dot as the core and cysteine as the transition layer, having artesunate loaded around, adopting gelatin as the wall material, and having three-layer packaging as well as a four-layer structure. Being in an ellipsoidal shape, the capsule has a capsule diameter of 180-220nm, and has observable fluorescence emission. The preparation method specifically comprises: first preparing a gelatin solution, adding a CdTe quantum dot solution into the 2% gelatin solution for adsorbing cysteine, conducting 10-fold dilution with ultrapure water, adding an artesunate anhydrous ethanol solution dropwisely, and adding an anhydrous sodium sulfate aqueous solution and a sodium hydroxide solution, adjusting the pH, then adding 10 microliters of a formaldehyde solution, and carrying out dialysis as well as freeze drying, thus obtaining a CdTe quantum dot-containing nano-artesunate capsule product. The preparation method of the invention combines a drug and a fluorescent marker, embeds them jointly inside the nano-capsule, and is simple to operate. The prepared capsule can well maintain the fluorescence characteristics, and can be applied in real-time monitoring of the laws of transmission and distribution as well as capsule breaking and release of a nano-drug in vivo.
A soft chew nutritional supplement for an animal, such as a dog or cat, is provided. The soft chew includes (a) palm oil and/or palm oil constituent, (b) palm kernel oil and/or coconut oil, and (c) at least one other oil. The method of manufacturing the soft chew typically includes partially curing the soft chew at -79 to 0°C before packaging the soft chew, and then allowing the soft chew to fully cure while in the packaging at room temperature. To achieve the desired processing and curing of the soft chew, the ratio of the total amount of the components (a) and (b) to the total amount of the (c) other oil ranges from 45:55 to 55:45. In addition, the components (a) and (b) have a Mettler Dropping Point ranging from 36o C to 40o C and are present in an amount of 4.5 wt. % to 6.5 wt. %.
In group B the implant crowns will be incorporated in a reverse pattern. During the first 16 weeks a cemented implant crown will be inserted and any possible cement residues will be removed according to best clinical procedure, while for the second period of 16 weeks patients will be fitted with a screw-retained single implant crown. Again, microbiological and clinical parameters will be obtained at the same intervals as in Group A.
Curcumin (CUR) is a natural polyphenol that holds promise for treating ulcerative colitis (UC), yet oral administration of CUR exhibits limited bioavailability and existing formulations for oral delivery of CUR often suffer from unsatisfactory loading capacity. This study presents hydroxyethyl starch-curcumin microspheres (HC-MSs) with excellent CUR loading capacity (54.52 %), and the HC-MSs can further encapsulate anti-inflammatory drugs dexamethasone (DEX) to obtain a combination formulation (DHC-MSs) with high DEX loading capacity (19.91 %), for combination therapy of UC. The microspheres were successfully engineered, retaining the anti-oxidative and anti-inflammatory activities of parental CUR and demonstrating excellent biocompatibility and controlled release properties, notably triggered by α-amylase, facilitating targeted drug delivery to inflamed sites. In a mouse UC model induced by dextran sulfate sodium, the microspheres effectively accumulated in inflamed colons and both HC-MSs and DHC-MSs exhibited superior therapeutic efficacy in alleviating UC symptoms compared to free DEX. Moreover, mechanistic exploration uncovered the multifaceted therapeutic mechanisms of these formulations, encompassing anti-inflammatory actions, mitigation of spleen enlargement, and modulation of gut microbiota composition. These findings underscore the potential of HC-MSs and DHC-MSs as promising formulations for UC, with implications for advancing treatment modalities for various inflammatory bowel disorders.
BACKGROUND: Several recent meta-analyses have identified the retromuscular plane as the preferred mesh position in ventral hernia repair. Open surgery used to be the standard technique for these procedures. However, new minimally invasive techniques with totally extraperitoneal access and mesh positioning in the retromuscular plane have evolved.
METHODS: Between September 2018 and March 2019, 18 consecutive patients with ventral hernia were treated endoscopically in the totally extraperitoneal technique. Depending on the localisation and size of the hernia, the appropriate access was chosen and an uncoated mesh was placed in the retromuscular space in all patients. Data of patients' characteristics as well as peri- and postoperative parameters were collected. One year after surgery, patients were asked about recurrence, pain and complications, using the questionnaire of the herniamed data base.
RESULTS: No intraoperative complications were noted. Postoperatively, there was one retromuscular seroma that did not need treatment, one temporary paralysis of the radial nerve and one pulmonary embolism. None of these complications led to persistent problems. 17 of 18 patients were available for follow-up. One year follow-up showed no hernia recurrence. One patient had pain at rest requiring treatment.
CONCLUSIONS: Totally extraperitoneal endoscopic hernia surgery is a safe and promising new technique that is also feasible in complex hernias and with satisfactory 1 year results. This technique can combine the advantages of minimally invasive surgery with those of extraperitoneal mesh placement.
The probiotic preparation selected for this study will contain use three species of probiotic bacterias namely Lactobacillus rhamnosus - ATCC 21052, Lactobacillus plantarum - ATCC 8014 and Bifidobacterium longum subsp. Infantis-ATCC 15707 at the dose of one billion (10 9 ) CFU/g of product (Total 3x10 9 CFU/g).
A large weight loss as a result of a longer period (\>30 days) of starvation or semi-starvation will result in a metabolic adaptation to the decreased food intake. To prevent the degradation of muscle mass into gluco- and ketogenic amino acids to be used for energy production, a shift from gluconeogenesis to lipolysis occurs. Lipids therefore become the primary energy fuel, and the body adapts to use ketone bodies instead of glucose. The reduction in glucose metabolism results in a decreased need for amino acids for use in gluconeogenesis. This means that less amino acids are needed for gluconeogenesis and therefore important muscle mass is preserved. At the same time as the lipid stores are degraded, an intracellular depletion of phosphate, potassium and magnesium occurs. The serum levels of these electrolytes stay within the normal range as long as the body is in the adaptive starvation state. A too quick reintroduction of food to the body will result in a major glucose-induced increase in insulin secretion that will stimulate the transport of glucose, phosphate, potassium and magnesium from plasma into the cells. Because the extracellular blood volume is much smaller than the intracellular, an influx of these electrolytes to the intracellular space will result in a quick and large decrease in the plasma levels. Likewise, an influx of glucose means that it again can enter the glucolysis, and the need for phosphate and the co-factor thiamine, for the production of ATP, will increase. The increased production of adenosine triphosphate (ATP) will activate membrane pumps and reestablish the membrane potential. This means that sodium will be transported from the large intracellular space to the small extracellular, with subsequent fluid retention and edema formation.

Therefore a slowly introduced diet low in sodium and high in slowly absorbed carbohydrates might prevent the development of refeeding syndrome.
LID021201 contact lenses worn in both eyes for 7 days. Lenses will be removed nightly for cleaning and disinfection with OPTI-FREE multipurpose solution.
According to the present invention, eight human RING-CH-containing genes are human transmembrane ubiquitin ligase proteins, are homologues of the viral K3-family, and perform functions similar to their viral counterparts. One of these proteins, MARCH-IV, is able to downregulate MHC I and CD4 in a fashion similar to that afforded by the viral immune evasion proteins. This is the first cellular gene product identified that downregulates surface expression of MHC I. The MARCH-family of proteins regulates endocytosis of cell surface receptors (e.g., transferrin receptor, histocompatibility antigens and Fas; type I as well as type II transmembrane domains) via ubiquitination. Particular embodiments provide drug targets for inhibiting the internalization and degredation of various cell surface receptors. Further embodiments provide methods for treating or preventing cancer and other disorders (e.g., leukemia, mental retardation, and L-thalassemia), which methods comprise the administration of a MARCH antagonist or pharmaceutical composition thereof. Screening methods for identification of therapeutic compounds that are modifiers of MARCH activity, are also encompassed by the present invention.
BACKGROUND: Resistance mechanisms to combination therapy with dabrafenib plus trametinib remain poorly understood in patients with BRAFV600E-mutant advanced non-small-cell lung cancer (NSCLC). We examined resistance to BRAF inhibition by single CTC sequencing in BRAFV600E-mutant NSCLC.
METHODS: CTCs and cfDNA were examined in seven BRAFV600E-mutant NSCLC patients at failure to treatment. Matched tumour tissue was available for four patients. Single CTCs were isolated by fluorescence-activated cell sorting following enrichment and immunofluorescence (Hoechst 33342/CD45/pan-cytokeratins) and sequenced for mutation and copy number-alteration (CNA) analyses.
RESULTS: BRAFV600E was found in 4/4 tumour biopsies and 5/7 cfDNA samples. CTC mutations were mostly found in MAPK-independent pathways and only 1/26 CTCs were BRAFV600E mutated. CTC profiles encompassed the majority of matched tumour biopsy CNAs but 72.5% to 84.5% of CTC CNAs were exclusive to CTCs. Extensive diversity, involving MAPK, MAPK-related, cell cycle, DNA repair and immune response pathways, was observed in CTCs and missed by analyses on tumour biopsies and cfDNA. Driver alterations in clinically relevant genes were recurrent in CTCs.
CONCLUSIONS: Resistance was not driven by BRAFV600E-mutant CTCs. Extensive tumour genomic heterogeneity was found in CTCs compared to tumour biopsies and cfDNA at failure to BRAF inhibition, in BRAFV600E-mutant NSCLC, including relevant alterations that may represent potential treatment opportunities.
Despite the existence of an OSHA standard for hearing conservation, noise-induced hearing loss continues to be one of the most prevalent occupational conditions. Furthermore, hearing loss rates appear to vary significantly between industrial locations with similar measured noise exposure levels. The factors that determine an effective hearing conservation program remain poorly understood. The effective use of hearing protection, believed to be a critical component of such programs, is felt to be highly variable in real world situations. Provocative new data by our research group indicate that much of the preventable hearing loss in a large industrial workforce is occurring not among the workers in the highest ambient noise areas, but instead among employees working in areas where measured ambient median noise exposures are close to or even slightly below the current OSHA action level (85dBA for an 8 hour time weighted average). One possible reason could be that the use of hearing protection is currently less effective in such areas of lower or intermittent noise compared to high noise areas. Since in many worksites, the majority of workers are exposed to moderate noise levels, there is an urgent need to better understand how to prevent hearing loss in these settings. There are also currently no national guidelines for ensuring correct fit and function of hearing protection, and there is an urgent need to find ways to promote the correct use of hearing protective devices. This study will assess the impact of hearing protector fit testing and daily noise exposure monitoring, with major implications for hearing conservation practice, and the wider prevention of noise-induced hearing loss. It will also explore the role of hearing protective devices in areas of median noise exposure less than 85dBA.

This proposed study is a worksite intervention trial of a new technology to reduce occupational noise-induced hearing loss. The intervention will test the effectiveness of a noise exposure dosimeter, the QuietDose - essentially a small microphone connected to a noise logging device about the size of a beeper- that measures a worker's daily noise "dose", as well as peak noise exposure, inside of the worker's hearing protectors. Workers and the study coordinator receive daily feedback about noise exposures (if the device was used outside of the study it would be safety personnel that received the feedback outside of the workers themselves). Such feedback will allow steps to be taken to minimize such exposures, such as behavioral adjustments and improved awarenessThe goal of this study is to determine whether daily assessment and feedback of workers' noise exposures leads to more effective use of hearing protection and prevention of noise-induced hearing loss. The proposed study will take advantage of the unique working relationship between a research institution (the Yale Occupational and Environmental Medicine Program) and a major industrial corporation (Alcoa, Inc.) to conduct this intervention trial at several of the company's facilities.
A protein complex comprising a carrier protein and phosphorylcholine (PCHO/CHOP/PC/C5H14NO4P) for treating and/or preventing a virus infection. The carrier protein may be a virus protein or a bacterial protein. The protein complex may induce or increase the amount of anti-phosphorylcholine antibodies in the individual. The viral infection may be a viral infection, such as influenza, adenovirus, respiratory syncytial virus (RSV), rhinovirus, or coronavirus, e.g. SARS-CoV-1 or SARS-CoV-2. The phosphorylcholine protein complex may bind to the viral surface proteins of the virus. Binding of the phosphorylcholine to the virus protein may permit virus entry into a target cell. Also claimed is a separate invention relating to an anti-phosphorylcholine antibody which binds to a complex comprising a virus protein and phosphorylcholine for use in treating and/or preventing a virus infection in an individual. A further embodiment is a method and use for predicting the prognosis of a virus infection by determining the amount of anti-phosphorylcholine antibodies in a sample from a subject. A further embodiment is a method for identifying an individual in need of anti-viral therapy by predicting the prognosis of the infection. The antibodies may elicit an immune response to clear the virus upon binding to the complex.
Subjects will receive a daily dose of 90 mg Fasudil for 42 days (open-label period 1). After Period 1 is complete, if the subject is a responder to Fasudil 90 mg/day, they will be randomized to either Fasudil 90 mg/day or a placebo for 6 weeks (double-blind period 1), then crossover to the other arm for 6 weeks (double-blind period 2).
Fifteen adult outpatients with high functioning autism or Asperger's Syndrome will be recruited. Fifteen healthy volunteers matched for age and IQ will also be recruited. Participants will undergo an fMRI scan. During the scan they will perform a task. The paradigm is designed to test control inhibition, face processing and language. Therefore, it includes a go-no go test, a face emotion discrimination test and a linguistic sound. The subjects are shown a series of faces with happy or sad expressions in random order. Each face presentation is accompanied by either a standard or variant sound. The sound stimulus is the English phoneme /oe/. The variant sound was created by raising the frequency of the standard sound by 20%. The task consists of four blocks. During each block the subjects are asked to press a button when they see a happy or sad face depending on the block. Each block consists of 96 trials lasting 2 seconds and an initial and final fixation period of 40 sec. For each trial the target image is projected for 500 ms. There is 1250 ms fixation time allowed for response and 250 ms for jitter. Twenty-four of the 96 trials are no go trials and 16/96 are sound oddball trials. The oddball is at least two trials apart (between two variant sounds there are at least two standard sounds). There are 24 faces displayed in total, 12 female and 12 male. Faces switch every 16 trials. Face genders are balanced. The faces were selected with over 80% congruency except for two faces with congruency of over 72%. The correlation between sound (2 conditions: standard versus variant) and target condition (go-no go) is zero. The task was piloted on healthy controls and autistic adults. All subjects performed well.
As a non-invasive treatment, Ultrasound Hyperthermia has received increasing interest for the treatment of cancer.Many studies have shown that Therapeutic Ultrasound is safe and effective. Eligible patients were randomly assigned by using permutated blocks designed for each site to receive either Ultrasound Hyperthermia combined with chemotherapy (Arm A) or chemotherapy alone(Arm B).Chemotherapy will be conducted as follows. For Squamous cell carcinoma of head and neck,it will be administrated with Docetaxel(at a dose of 75 mg per square meter of body-surface area and intravenous infused in 1 hr at day 1rt), Cisplatin(at a dose of 75 mg per square meter of body-surface area and intravenous infused in 1 hr at day 1rt) and Fluorouracil(at a dose of 75 mg per square meter of body-surface area and intravenous infused last 5 days) . For other types of cancer,the treatments will be administrated in accord with the guideline.In addition,Ultrasound Hyperthermia will be conducted 5 times(day 1rt,3rd,5th,7th,9th) in Arm A. Patients in arm B will receive chemotherapy only. One cycle comprises a period of 3 weeks (21 days).All patients will receive 2 cycles in both arms. All the patients eligible for the operation will take surgery. After treatment，some patients with advanced unresectable cancer may be down-staged from stage IV, and will regain the opportunity of operation.